Anti-CD44 mAb remodels biological behaviors of spheroid cells with stemness from human ovarian cancer cell line SKOV-3

作     者：GU Chao DU YongRui GAO Yan YAO Zhi GU Xin ZHANG QiuYue XU JingJing DENG WeiMin 

作者机构：Tianjin Key Laboratory of Cellular and Molecular ImmunologyTianjin Medical UniversityTianjin 300070China Department of GynecologyTianjin Central Gynecology and Obstetrics HospitalTianjin 300100China 

出 版 物：《Chinese Science Bulletin》 (Chinese Science Bulletin)

年 卷 期：2012年第57卷第11期

页      面：1288-1297页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China (30670801) the Tianjin Research Program of Application Foundation and Advanced Technology (06YFJMJC08300) 

主　　题：单克隆抗体 生物学行为 CD44 体细胞 细胞株 卵巢癌 人类 干性 

摘      要：There is accumulating evidence that cancer stem cells (CSCs) play an important role in tumor progression. Novel strategies targeting CSCs have been widely researched. In the present study, we explored whether such CSCs existed in human ovarian cancer (OVCA) cell line and whether anti-CD44 antibody had effects on such subpopulation. We isolated and identified spheroid cells from SKOV-3. Then we used A3D8, an anti-CD44 mAb to treat spheroid cells with so-called stemness. Effects of A3D8 on spheroid cells biological behaviors were examined. Our findings showed that there was a small subpopulation that had so-called stemness in SKOV-3 cell line. Against spheroid cells, A3D8 can (1) inhibit cell proliferation; (2) change cell cycle distribution and expression of p21, CDK2 and cyclinA; (3) enhance cisplatin (DDP)-induced apoptosis; (4) promote cell differentiation; (5) inhibit clone formation efficiency; (6) reduce invasive efficacy; (7) inhibit tumorigenicity. Thus, to sum up points which we have just showed, spheroid cells isolated from SKOV-3 can be used as an appropriate in vitro model for relevant study of human ovarian CSCs. And our results reasoned that anti-CD44 therapy may become a potential promising strategy for OVCA treatment.